Peter Lenting obtained his PhD cum laude at the medical faculty of the University of Amsterdam, the Netherlands in 1996. He was appointed Associate Professor of Haematology at the University Medical Center in Utrecht, the Netherlands in 2000. Between 2007 and 2009, he held a position of Director of Protein Discovery at Crucell Holland (Leiden, the Netherlands). In March 2009, he joined Inserm as Director of Research. His research activities are mainly focussed on the biology of the Factor VIII/von Willebrand factor (FVIII/VWF) complex and their related disorders haemophilia A and von Willebrand disease. He was an elected member of the council of the International Society of Thrombosis and Haemostasis (ISTH; 2012-2018), and was chair of the ISTH-WHO-liaison committee (2012-2018). Dr. Lenting was awarded the Prix Danièle Hermann (Foundation for Cardio-vascular Research, Institut de France) for his research activities in 2009. In 2018, he has co-founded Laelaps Therapeutics.